Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX) Stock Quotes and News

Idenix Pharmaceuticals, Inc. (IDIX) 4.88 0.12

Price Open:	4.165	Day's Range:	0.00000 - 5.85990
Price Close:	4.19	52wk Range:	0.00000 - 15.25
Price Day Change:	0.12	Volume:	1,031,381
Price % Change:	2.86	Market Cap:	577.4M
Bid:	4.31000	PE Ratio:	0
Ask:	4.88000	EPS Diluted:	-0.595

Trade IDIX NOW!

The Latest On IDIX

Idenix Announces Data Presentation at the 48th Annual Meeting of the European Association for the Study of the Liver (EASL) 4/8/13 4:08pm

Mid-Afternoon Market Update: VrinetX Falls as Veeco Continues to Boost 3/25/13 3:37pm

UPDATE: Bank of America Downgrades Idenix Pharmaceuticals to Underperform on Unfavorable Patent Ruling 3/25/13 2:01pm

Mid-Day Market Update: Markets Turn Red, Apollo Group Surges On Upbeat Results 3/25/13 1:11pm

Mid-Morning Market Update: Markets Rise On Cyprus Deal, Dollar General Posts Higher Profit 3/25/13 11:03am

Morning Market Losers 3/25/13 10:15am

Benzinga's Top Pre-Market Losers 3/25/13 8:39am

UPDATE: JP Morgan Cuts PT to $13 on Idenix Pharmaceuticals on Model Update Post Q4 2/26/13 2:16pm

13-F Alert: Baupost Group Adds AIG Shares and Microsoft Call Options 2/13/13 7:16pm

Idenix Pharma Will Cease IDX 184, IDX 19368 2/4/13 5:38pm

UPDATE: Idenix Pharma to Discontinue IDX184, IDX19368 Programs 2/4/13 5:15pm

UPDATE: Wedbush Downgrades Idenix Pharmaceuticals to Neutral on Long-Term Clarity 1/30/13 8:51am

Press Releases

Idenix Pharmaceuticals to Present at Three Upcoming Healthcare Conferences 5/8/13 GlobeNewswire

Idenix Pharmaceuticals Reports First Quarter 2013 Financial Results 4/30/13 GlobeNewswire

Idenix Reports Favorable Resistance Profile for IDX719, a Potent, Pan-Genotypic HCV NS5A Inhibitor, at EASL Meeting 4/24/13 GlobeNewswire

Idenix Announces Data Presentation at the 48th Annual Meeting of the European Association for the Study of the Liver (EASL) 4/8/13 GlobeNewswire

Idenix Pharmaceuticals Announces Decision by the United States Patent and Trademark Office Patent Trial and Appeal Board in the First Phase of the Interference 3/22/13 GlobeNewswire

Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences 2/26/13 GlobeNewswire

Idenix Pharmaceuticals Reports Fourth Quarter and Year Ended 2012 Financial Results 2/25/13 GlobeNewswire

Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences 2/5/13 GlobeNewswire

Idenix Pharmaceuticals Provides Update on IDX184 and IDX19368 Development Programs 2/4/13 GlobeNewswire

Idenix Pharmaceuticals Announces Collaboration With Janssen to Initiate Phase II All-Oral Combination Studies Including IDX719, Simeprevir (TMC435) and TMC647055 for the Treatment of Hepatitis C Virus (HCV) 1/28/13 GlobeNewswire

Idenix Pharmaceuticals to Present at the 31st Annual J.P. Morgan Healthcare Conference 1/2/13 GlobeNewswire

Idenix Pharmaceuticals to Present at the Oppenheimer 23rd Annual Healthcare Conference 12/5/12 GlobeNewswire

Get the latest IDIX stock news on the web. Get the latest stock quotes and much more - Benzinga is the source for Idenix Pharmaceuticals, Inc. stock price.

Partner Headlines

Seth Klarman Buys BP, AIG, Elan Corp, Sells News Corp., Oracle 5/14/13

The Far-Off Four, 52-week Lows Held by Gurus 5/11/13

Numbers for the Day 5/8/13

IDIX at 52-Week Low - Gurus Cohen, Klarman Holding On 4/3/13

Seth Klarman - IDIX Mega Shares and New FDA 'Breakthrough' Track 3/29/13

Setback for Idenix Pharma - Analyst Blog 3/28/13

Idenix Reports In-Line 4Q Loss - Analyst Blog 3/1/13

Seth Klarman's Baupost Group Buys AIG, Idenix Pharmaceuticals, Sells Hewlett-Packard, Oracle, ... 2/14/13

Pipeline Setback for Idenix - Analyst Blog 2/7/13

New Ratings: CHKP, DKL, GOOG, IDIX, VOD, WDAY 11/28/12

Seth Klarman Buys Rovi Corp, Novagold, Idenix Pharmaceuticals, Sells Hewlett-packard, Microsoft ... 11/14/12